Keros commenced a randomized, double-blind, placebo-controlled, two-part Phase 1 clinical trial to evaluate single and multiple ascending doses of KER-065 in healthy volunteers Keros expects to report initial data from this Phase 1 clinical trial in the first quarter of 2025Preclinical data showed potential proof-of-mechanism of KER-065 for the treatment of obesityKeros believes these preclinical data support developing KER-065 for the treatment of obesity, and Keros plans to initiate a proof-of-concept trial of KER-065 in obese patients following completion of this Phase 1 clinical trial LEXINGTON, Mass., Jan.

Keros开始了一项随机，双盲，安慰剂对照，评估健康志愿者单次和多次递增剂量KER-065的两部分1期临床试验Keros预计将在2025年第一季度报告该1期临床试验的初步数据临床数据显示KER-065治疗肥胖症的机制的潜在证据克罗斯认为，这些临床前数据支持开发用于治疗肥胖症的KER-065，Keros计划在完成第一阶段临床试验后，在肥胖患者中启动KER-065的概念验证试验。

03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it plans to develop KER-065, a novel ligand trap designed to bind to and inhibit TGF-ß ligands, including myostatin (GDF8) and activin A, for the treatment of obesity.

2024年3月3日（环球通讯社）--Keros Therapeutics，Inc.（“Keros”或“we”）（纳斯达克：KROS），一家临床阶段的生物制药公司，专注于开发和商业化新疗法，以治疗与转化生长因子β（“TGF-β”）蛋白家族功能失调信号相关的多种疾病患者，今天宣布计划开发KER-065，这是一种新型配体陷阱，旨在结合并抑制TGF-β配体，包括肌肉生长抑制素（GDF8）和激活素a，用于治疗肥胖症。

“Obesity is a complex and chronic disease associated with numerous comorbidities and a growing prevalence in patients. We believe there is a need for additional treatment options, including one that leads to weight loss without an associated loss of muscle and a potential for frailty. Based on our preclinical data, we believe that KER-065 has the potential to treat obesity without those limitations, by increasing skeletal muscle, reducing fat mass through an increase in energy expenditure, improving insulin sensitivity and improving cardiac function,” said Jasbir S.

“肥胖是一种复杂的慢性疾病，与许多合并症有关，并且在患者中的患病率不断上升。我们认为需要额外的治疗选择，包括导致体重减轻而不伴有肌肉损失和虚弱的可能性。根据我们的临床前数据，我们认为KER-065有可能在不受这些限制的情况下治疗肥胖离子，通过增加骨骼肌，通过增加能量消耗减少脂肪量，改善胰岛素敏感性和改善心脏功能，”Jasbir S。

Seehra, Ph.D., President and Chief Executive Officer of Keros. “.

Keros总裁兼首席执行官Seehra博士。“。